{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026195","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.510301+00:00","generated_at":"2026-05-17T14:35:49.729355+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions","bullets":["GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).","Cash $106.3M at June 30 (down from $119.3M at March 31); operating cash burn $12.8M in Q2.","FDA IDE applications submitted for nsPFA cardiac surgical clamp and 360° catheter AF pivotal studies.","Over 140 benign thyroid nodule patients treated; expanded pilot program; post-market study enrollment planned Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026195","json":"https://secwatch.observer/filing/0001437749-25-026195.json","markdown":"https://secwatch.observer/filing/0001437749-25-026195.md","text":"https://secwatch.observer/filing/0001437749-25-026195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/0001437749-25-026195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774925026195/plse20250604_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:35:49.729355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}